Zantac (Ranitidine) Concealed Cancer Risk Canadian Class Action

Zantac (Ranitidine) Concealed Cancer Risk Canadian Class Action

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+'://platform.twitter.com/widgets.js';fjs.parentNode.insertBefore(js,fjs);}}(document, 'script', 'twitter-wjs');

lang: en_US

Share

Active

Join This Class Action

.documentsbtn span.plus,

.documentsbtn span.minus{

display:none;

}

.documentsbtn[aria-expanded="false"] span.plus,

.documentsbtn[aria-expanded="true"] span.minus{

display:block;

float: left;

margin: 0 10px 0px 0;

}

+ - Documents (2)

QC Jul 17, 2020 [en]

Amended Application for Authorization

QC Oct 02, 2019 [en]

Application for Authorization

CONSUMER LAW GROUP has launched a Canada-wide class action lawsuit against Sanofi, GlaxoSmithKline, Sandoz, Pharmascience, Apotex, Pro Doc, Sanis Health, and Sivem Pharmaceuticals for knowingly manufacturing and selling a drug that they knew was unsafe to millions of Canadians and for their intentional concealment of the risk of cancer associated with the popular heartburn medication, Zantac.

Zantac contains the active ingredient ranitidine. When ingested, ranitidine metabolizes into N-nitrosodimethylamine (NDMA) which Health Canada, the FDA, the EPA, and the World Health Organization classify as a probable carcinogen.

Ranitidine is available in Canada over-the-counter (for example, under the brand name Zantac and as generics) and by prescription (as generics). Over-the-counter ranitidine is approved to prevent and relieve heartburn associated with acid indigestion and sour stomach. Prescription ranitidine drugs are used to reduce stomach acid for the treatment and prevention of various gastrointestinal conditions, such as hea